Key result
Combined serum TGF-β1 and PDGF-BB identifies stable CAD with high accuracy, yielding ~0.92 AUC.
Why the study?
The study was conducted to compare serum levels of TGF-beta and PDGF-BB across patients with normal coronary arteries, stable CAD, and ACS, and to evaluate their potential diagnostic and discriminatory value.
Do serum TGF-β1 and PDGF-BB levels differentiate between normal coronary arteries, stable CAD, and acute coronary syndrome in adults undergoing coronary angiography?
Cross-Sectional (n=176)
No
Do serum TGF-β1 and PDGF-BB levels differentiate between normal coronary arteries, stable CAD, and acute coronary syndrome in adults undergoing coronary angiography?
Effect estimate: AUC 0.924 (95% CI 0.902-0.960)
p-value: p=<0.001
Serum TGF-β1 and PDGF-BB levels are significantly elevated in stable CAD and suppressed in ACS, offering high diagnostic accuracy for distinguishing stable CAD from normal coronary anatomy and identifying acute plaque destabilization.
May support biomarker panels for stable CAD diagnosis; leaves open prospective validation before clinical adoption.
To compare serum levels of Transforming Growth Factor-Beta (TGF-β) and Platelet-Derived Growth Factor-BB (PDGF-BB) among patients with normal coronary arteries (NCA) and those with coronary artery disease (CAD) subclasses [stable CAD and acute coronary syndrome (ACS)], and to evaluate their potential diagnostic value and discriminatory power, particularly in identifying stable CAD. This single-center, cross-sectional study included 176 patients who underwent coronary angiography. Participants were classified into normal coronary artery (NCA; symptomatic control), stable CAD, and ACS groups. Demographic, clinical, and biochemical data were recorded. Blood samples were collected for the analysis of TGF-β1 and PDGF-BB levels using ELISA kits. Hypertension and diabetes mellitus were significantly more prevalent in the stable CAD group compared to others ( p < 0.001). Both TGF-β and PDGF-BB levels were significantly elevated in patients with stable CAD compared to individuals with normal coronary arteries and those with ACS ( p < 0.001). Multivariate regression analysis identified hypertension, diabetes, TGF-β, and PDGF-BB as independent predictors of stable CAD ( p < 0.01 for all). ROC curve analysis demonstrated good diagnostic performance for TGF-β and PDGF-BB individually (AUC = 0.847, 0.798, respectively), with combined assessment further improving accuracy (AUC = 0.924). Serum TGF-β and PDGF-BB levels are significantly increased in stable CAD patients relative to those with ACS and normal coronary anatomy. The combined evaluation of these biomarkers provides high diagnostic accuracy in distinguishing stable CAD, underscoring their potential role in the non-invasive assessment of chronic atherosclerotic disease. These findings support the use of TGF-β and PDGF-BB as complementary biomarkers for early identification and risk stratification in stable CAD.
No takes yet. Share an insight, caveat, or question.
Küçüksevgili et al. (2026) conducted a cross-sectional in Coronary Artery Disease (n=176). Serum TGF-β1 and PDGF-BB levels vs. Normal coronary arteries and acute coronary syndrome was evaluated on Diagnostic accuracy of combined TGF-β1 and PDGF-BB for stable CAD (AUC 0.924, 95% CI 0.902-0.960, p=<0.001). Combined evaluation of serum TGF-β1 and PDGF-BB levels demonstrated high diagnostic accuracy (AUC 0.924) in distinguishing stable coronary artery disease from normal coronary anatomy and acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: